- Title:
Contract awards - Time:
07:00:03 - Date:
16 Oct 2020 - Category:
Corporate updates - ID:
2591C
16 October 2020
Physiomics plc
("Physiomics" or "the Company")
Contract awards
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded further contracts of undisclosed value for projects with existing clients Bicycle Therapeutics plc ("Bicycle") and Merck KGaA ("Merck").
The project with Bicycle is the eighth signed with this high-profile UK biotech company, spanning four different assets within its pipeline, and involves population pharmacokinetic analysis of clinical data from one of these assets. The project with Merck is an extension of one of the projects previously announced for calendar year 2020 in what is now the third year of work under the Master Services Agreement announced in November 2017.
It is anticipated that both projects will be completed over the next four months.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.
For more information please visit:
www.linkedin.com/company/physiomics-plc/
Contract awards07:00:0316 Oct 2020Corporate updates2591C